Nora Maureen Rooney

Array ( [id] => 20219883 [patent_doc_number] => 20250282814 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-09-11 [patent_title] => PROCESS OF PURIFICATION OF PROTEIN [patent_app_type] => utility [patent_app_number] => 19/092641 [patent_app_country] => US [patent_app_date] => 2025-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14922 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19092641 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20219883 [patent_doc_number] => 20250282814 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-09-11 [patent_title] => PROCESS OF PURIFICATION OF PROTEIN [patent_app_type] => utility [patent_app_number] => 19/092641 [patent_app_country] => US [patent_app_date] => 2025-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14922 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19092641 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20173021 [patent_doc_number] => 12391753 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-08-19 [patent_title] => Antigen binding molecule formats [patent_app_type] => utility [patent_app_number] => 18/977144 [patent_app_country] => US [patent_app_date] => 2024-12-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 43 [patent_figures_cnt] => 49 [patent_no_of_words] => 41819 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 152 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18977144 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19526698 [patent_doc_number] => 20240350600 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-24 [patent_title] => NOVEL IMMUNOTHERAPEUTIC MOLECULES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/754670 [patent_app_country] => US [patent_app_date] => 2024-06-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16413 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18754670 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19526698 [patent_doc_number] => 20240350600 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-24 [patent_title] => NOVEL IMMUNOTHERAPEUTIC MOLECULES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/754670 [patent_app_country] => US [patent_app_date] => 2024-06-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16413 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18754670 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19464217 [patent_doc_number] => 20240317886 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-26 [patent_title] => BINDING AGENTS TARGETING TROP2-EXPRESSING TUMOR CELLS [patent_app_type] => utility [patent_app_number] => 18/664070 [patent_app_country] => US [patent_app_date] => 2024-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 91729 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18664070 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19464218 [patent_doc_number] => 20240317887 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-26 [patent_title] => BINDING AGENTS TARGETING TROP2-EXPRESSING TUMOR CELLS [patent_app_type] => utility [patent_app_number] => 18/664091 [patent_app_country] => US [patent_app_date] => 2024-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 91577 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18664091 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19961625 [patent_doc_number] => 12331109 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-06-17 [patent_title] => Antigen binding molecule formats [patent_app_type] => utility [patent_app_number] => 18/640981 [patent_app_country] => US [patent_app_date] => 2024-04-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 43 [patent_figures_cnt] => 48 [patent_no_of_words] => 41811 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 132 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18640981 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19816777 [patent_doc_number] => 20250074984 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-03-06 [patent_title] => VARIANT IgG FC POLYPEPTIDES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/614199 [patent_app_country] => US [patent_app_date] => 2024-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 161824 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18614199 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19360880 [patent_doc_number] => 20240262914 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-08 [patent_title] => MULTISPECIFIC BINDING CONSTRUCTS AGAINST CHECKPOINT MOLECULES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/609108 [patent_app_country] => US [patent_app_date] => 2024-03-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 54494 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 134 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18609108 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19543182 [patent_doc_number] => 20240360218 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-31 [patent_title] => ANTI-PD-L1 AND IL-2 CYTOKINES [patent_app_type] => utility [patent_app_number] => 18/592425 [patent_app_country] => US [patent_app_date] => 2024-02-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 125380 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18592425 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19543182 [patent_doc_number] => 20240360218 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-31 [patent_title] => ANTI-PD-L1 AND IL-2 CYTOKINES [patent_app_type] => utility [patent_app_number] => 18/592425 [patent_app_country] => US [patent_app_date] => 2024-02-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 125380 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18592425 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19234015 [patent_doc_number] => 20240191207 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-13 [patent_title] => METHODS AND COMPOSITIONS FOR INDUCIBLE EXTRACELLULAR MEMBRANE CAPTURE OF MONOCLONAL IMMUNOGLOBULINS SECRETED BY HYBRIDOMAS [patent_app_type] => utility [patent_app_number] => 18/443701 [patent_app_country] => US [patent_app_date] => 2024-02-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31511 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18443701 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19202849 [patent_doc_number] => 20240174748 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-30 [patent_title] => VARIABLE REGIONS FOR NKP46 BINDING PROTEINS [patent_app_type] => utility [patent_app_number] => 18/432126 [patent_app_country] => US [patent_app_date] => 2024-02-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32416 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 282 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18432126 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19332623 [patent_doc_number] => 20240247053 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-25 [patent_title] => COMBINATIONS FOR ALLERGY THERAPY [patent_app_type] => utility [patent_app_number] => 18/415554 [patent_app_country] => US [patent_app_date] => 2024-01-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14223 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18415554 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19692858 [patent_doc_number] => 20250011403 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-09 [patent_title] => NUCLEIC ACIDS, VECTORS, AND CELLS THAT ENCODE ANTI-SP17 ANTIBODIES AND OTHER SP17 BINDING PROTEINS [patent_app_type] => utility [patent_app_number] => 18/408386 [patent_app_country] => US [patent_app_date] => 2024-01-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13041 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 163 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18408386 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19343644 [patent_doc_number] => 20240252607 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-01 [patent_title] => IMMUNOTHERAPEUTIC MOLECULES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/395074 [patent_app_country] => US [patent_app_date] => 2023-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16388 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18395074 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19112819 [patent_doc_number] => 20240124569 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-18 [patent_title] => ANTIBODIES AND ASSAYS FOR CCL14 [patent_app_type] => utility [patent_app_number] => 18/390942 [patent_app_country] => US [patent_app_date] => 2023-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28759 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18390942 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19112819 [patent_doc_number] => 20240124569 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-18 [patent_title] => ANTIBODIES AND ASSAYS FOR CCL14 [patent_app_type] => utility [patent_app_number] => 18/390942 [patent_app_country] => US [patent_app_date] => 2023-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28759 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18390942 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19265375 [patent_doc_number] => 20240209074 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-27 [patent_title] => METHODS OF TREATING ALLERGY USING ANTI-BET V 1 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/545795 [patent_app_country] => US [patent_app_date] => 2023-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26582 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18545795 [rel_patent_id] =>[rel_patent_doc_number] =>)